{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:01:08Z","timestamp":1771326068468,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Faculty of Medicine, University of Porto (FMUP)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The potential benefits of drug repurposing have gained attention as an alternative to developing de novo drugs. The potential of using central nervous system (CNS) drugs as anticancer drugs has been explored in several types of human cancers, such as breast and colon cancer, among others. Here, we examine the effect of the CNS drugs sertraline, paroxetine, and chlorpromazine on human squamous carcinoma cells of the bladder (UM-UC-5). After exposing UM-UC-5 cells to increased concentrations of each drug for 48 h, we assessed their metabolic activity using an MTT assay. Based on those results, we calculated cell viability and the half-maximal inhibitory concentration (IC50) values. The results suggest that the CNS drugs were effective against UM-UC-5 in the order of potency of sertraline &gt; chlorpromazine &gt; paroxetine. Interestingly, sertraline was more potent than 5-fluorouracil (5-FU), a widely used anticancer drug. This study demonstrated, for the first time, the promising anticancer activity of CNS drugs on human bladder cancer cells in vitro and supports the repurposing of CNS drugs to improve cancer treatment. Nevertheless, further studies are necessary to understand their mechanism of action and in vivo activity.<\/jats:p>","DOI":"10.3390\/pharmaceutics16020212","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T10:44:24Z","timestamp":1706697864000},"page":"212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-5520","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Gouveia","sequence":"first","affiliation":[{"name":"Center for the Study in Animal Science (CECA\/ICETA), University of Porto, Rua de D. Manuel II, Apt 55142, 4051-401 Porto, Portugal"},{"name":"Centre for Parasite Biology and Immunology, Department of Infectious Diseases, National Health Institute Dr. Ricardo Jorge, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5370-9586","authenticated-orcid":false,"given":"Eduarda","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer Statistiscs, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"Martin","year":"2016","journal-title":"Arab J. Urol."},{"key":"ref_3","first-page":"260","article-title":"Chronic inflammation and bladder cancer","volume":"25","author":"Michaud","year":"2007","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2004.04588.x","article-title":"Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment","volume":"93","author":"Shokeir","year":"2004","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40794-022-00161-x","article-title":"Urinary bladder Schistosoma haematobium-related squamous cell carcinoma: A report of two fatal cases and literature review","volume":"8","author":"Efared","year":"2022","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13027-023-00491-1","article-title":"The trend of schistosomiasis related bladder cancer in the laze zone, Tanzania: A retrospective review over 10 years period","volume":"18","author":"Yohana","year":"2023","journal-title":"Infect. Agent. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2015.01.018","article-title":"Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer","volume":"359","author":"Gouveia","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317692247","article-title":"The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer","volume":"39","author":"Vale","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euo.2018.11.003","article-title":"Comparative effectiveness of treatment strategies for squamous cell carcinoma of the bladder","volume":"3","author":"Stensland","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"Drugs J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pantziarka, P., Sukhtame, V., Meheus, L., Sukhatme, V.P.V.V., and Bouche, G. (2017). Repurposing non-cancer drugs in oncology-how many drugs are out there?. bioRxiv, 1.","DOI":"10.1101\/197434"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology-patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2017.06.007","article-title":"Repurposing drugs in oncology: Next steps","volume":"3","author":"Verbaanderd","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","article-title":"Old wine in new bottles: Drug repurposing in oncology","volume":"866","author":"Antoszczak","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.3390\/cimb44100335","article-title":"Novel strategies for cancer combat: Drug combination using repurposed drugs induces synergistic growth inhibition of MCF-7 breast and HT-29 colon cancer cells","volume":"44","author":"Duarte","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Duarte, D., Falc\u00e3o, S.I., El Mehdi, I., Vilas-Boas, M., and Vale, N. (2022). Honeybee venom synergistically enhances the cytotoxic effect of CNS drugs in HT-29 colon and MCF-7 breast cancer cell lines. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030511"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Duarte, D., Nunes, M., Ricardo, S., and Vale, N. (2022). Combination of antimalarial and CNS drugs with antineoplastic agents in MCF-7 breast and HT-29 colon cancer cells: Biosafety evaluation and mechanism of action. Biomolecules, 12.","DOI":"10.3390\/biom12101490"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Duarte, D., Cardoso, A., and Vale, N. (2021). Synergistic growth inhibition of HT-29 colon and MCF-7 breast cancer cells with simultaneous and sequential combinations of antineoplastics and CNS drugs. Int. J. Mol. Sci., 10.","DOI":"10.3390\/ijms22147408"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Duarte, D., and Vale, N. (2022). Antidepressant drug sertraline against human cancer cells. Biomolecules, 12.","DOI":"10.3390\/biom12101513"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nunes, M., Duarte, D., Vale, N., and Ricardo, S. (2022). Pitavastatin and ivermectin enhance the efficacy of paclitaxel in chemoresistant high-grade serous carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14184357"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ribeiro, E., Ara\u00fajo, D., Pereira, M., Lopes, B., Sousa, P., Sousa, A.C., Coelho, A., R\u00eama, A., Alvites, R., and Faria, F. (2023). Repurposing benzotropine, natamycin and nitazoxanide using drug combination and characterization of gastric cancer cell lines. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030799"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4081\/oncol.2019.411","article-title":"Prospects for repurposing CNS drugs for cancer treatment","volume":"13","author":"Abdelaleem","year":"2019","journal-title":"Oncol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s43046-022-00137-0","article-title":"Drug repurposing: Re-inventing therapies for cancer without re-entering the development pipeline-a review","volume":"34","author":"Siddiqui","year":"2022","journal-title":"J. Egypt. Nat. Cancer Inst."},{"key":"ref_24","unstructured":"(2023, August 16). Sertraline|DrugBank Online. Available online: https:\/\/go.drugbank.com\/drugs\/DB01104."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kowalska, M., Nowaczyk, J., Fija\u0142kowski, \u0141., and Nowaczyk, A. (2021). Paroxetine-Overview of the Molecular Mechanisms of Action. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041662"},{"key":"ref_26","unstructured":"(2023, August 16). Paroxetine|DrugBank Online. Available online: https:\/\/go.drugbank.com\/drugs\/DB00715."},{"key":"ref_27","first-page":"495","article-title":"Fifty years chlorpromazine: A historical perspective","volume":"3","author":"Ban","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_28","unstructured":"(2023, August 18). Chlorpromazine|DrugBank Online. Available online: https:\/\/go.drugbank.com\/drugs\/DB00477."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"ref_31","first-page":"1","article-title":"Imatinib mesylate. Recent results","volume":"212","author":"Waller","year":"2018","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7150\/ijbs.22896","article-title":"The Role of G Protein-coupled Receptor Kinases in Cancer","volume":"14","author":"Yu","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chaudhary, P.K., and Kim, S. (2021). An Insight into GPCR and G-Proteins as Cancer Drivers. Cells, 10.","DOI":"10.3390\/cells10123288"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ghasemi, M., Turnbull, T., Sebastian, S., and Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312827"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832047","DOI":"10.3389\/fonc.2022.832047","article-title":"The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma","volume":"12","author":"Mazziotta","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liang, Y., and Turcan, S. (2022). Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020211"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mu, C., Peng, R.K., Guo, C.L., Li, A., Yang, X.M., Zeng, R., Li, Y.L., Gu, J., and Ouyang, Q. (2021). Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis. Bioorganic Med. Chem. Lett., 41.","DOI":"10.1016\/j.bmcl.2021.127997"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.biopha.2017.01.024","article-title":"A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors","volume":"87","author":"Radin","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Chang, X., Huang, Y., and He, D. (2023). The application of antidepressant drugs in cancer treatment. Biomed. Pharmacother., 157.","DOI":"10.1016\/j.biopha.2022.113985"},{"key":"ref_41","first-page":"2043","article-title":"Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: Dual activation of apoptosis and autophagy signaling by deregulating redox balance","volume":"10","author":"Chinnapaka","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","first-page":"277","article-title":"Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice","volume":"33","author":"Zolokov","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e98921","DOI":"10.1172\/jci.insight.98921","article-title":"Repurposing Sertraline Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib by Inducing Autophagy","volume":"3","author":"Jiang","year":"2018","journal-title":"JCI Insight"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/jcmm.14011","article-title":"Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3","volume":"23","author":"Jang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e201148","DOI":"10.1590\/s2175-97902022e201148","article-title":"Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells","volume":"58","author":"Cakil","year":"2022","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"635472","DOI":"10.3389\/fonc.2021.635472","article-title":"Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism with Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro","volume":"11","author":"Matteoni","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.taap.2006.11.012","article-title":"Paroxetine-induced apoptosis in human osteosarcoma cells: Activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation","volume":"218","author":"Chou","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cho, Y.W., Kim, E.J., Nyiramana, M.M., Shin, E.J., Jin, H., Ryu, J.H., Kang, K.R., Lee, G.W., Kim, H.J., and Han, J. (2019). Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation. Cancers, 11.","DOI":"10.3390\/cancers11010064"},{"key":"ref_49","first-page":"310","article-title":"Paroxetine-induced Ca2+ movement and death in OC2 human oral cancer cells","volume":"54","author":"Fang","year":"2011","journal-title":"Chin. J. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07853890109002093","article-title":"Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours","volume":"33","author":"Joensuu","year":"2001","journal-title":"Ann. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1177\/0960327110396523","article-title":"The mechanism of sertraline-induced [Ca2+]i rise in human OC2 oral cancer cells","volume":"30","author":"Chien","year":"2011","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0006-291X(84)80352-6","article-title":"Chlorpromazine: A potential anticancer agent?","volume":"125","author":"Darkin","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/CAD.0b013e32832ec041","article-title":"The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells","volume":"20","author":"Yde","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"ref_54","first-page":"687","article-title":"Chlorpromazine transport in membrane vesicles from multidrug resistant CCRF-CEM cells","volume":"39","author":"Syed","year":"1996","journal-title":"Biochem. Mol. Biol. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3858\/emm.2010.42.5.041","article-title":"Chlorpromazine activates p21Waf1\/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells","volume":"42","author":"Shin","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00280-021-04386-z","article-title":"Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2\/M cell cycle arrest, apoptosis, and autophagy","volume":"89","author":"Xu","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.18632\/oncotarget.28010","article-title":"Multifaceted effect of chlorpromazine in cancer: Implications for cancer treatment","volume":"12","author":"Brelidze","year":"2021","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","article-title":"Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response","volume":"40","author":"Matteoni","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41598-017-18457-w","article-title":"Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelminthic drugs capable of clinical repurposing","volume":"8","author":"Weeks","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_60","unstructured":"International Agency for Research on Cancer (2012). IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Human Biological Agents."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:43Z","timestamp":1760104363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["pharmaceutics16020212"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16020212","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}